Teva Pharmaceutical Industries Ltd
Close on Oct 19, 2026Market cap $48.13BP/E 68.9Yield –
Teva Pharmaceutical Industries Depreciation Expense (Per EBITDA Reconciliation) by Quarter
Depreciation Expense (Per EBITDA Reconciliation) ($M)
Teva Pharmaceutical Industries Depreciation Expense (Per EBITDA Reconciliation): $106M in Q3 2026, up 1.0% from a year earlier.
Where the Q3 2026 figure comes from
“|| Depreciation | 106 | 105 | 311 | 306”
Source: Form 8-K Earnings Release (0001171843-26-007054) ↗
Reported in SEC Form 10-K / Form 10-Q / Form 8-K Earnings Releases.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Teva Pharmaceutical Industries Depreciation Expense (Per EBITDA Reconciliation) ($M), quarterly Q4 2021–Q3 2026 [Data set]. Compiled from Teva Pharmaceutical Industries SEC filings and investor materials. https://stockdatahq.com/stocks/teva/kpis/ng-depr
See every metric in the Teva Pharmaceutical Industries KPI table. Data updated Nov 10, 2026.
See a number that looks wrong?